KR20190140486A - 항바이러스 화합물 - Google Patents
항바이러스 화합물 Download PDFInfo
- Publication number
- KR20190140486A KR20190140486A KR1020197036217A KR20197036217A KR20190140486A KR 20190140486 A KR20190140486 A KR 20190140486A KR 1020197036217 A KR1020197036217 A KR 1020197036217A KR 20197036217 A KR20197036217 A KR 20197036217A KR 20190140486 A KR20190140486 A KR 20190140486A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- independently
- aryl
- arylalkyl
- groups
- Prior art date
Links
- 0 C**(C)CCN Chemical compound C**(C)CCN 0.000 description 90
- GXGGNIQWBNKQPJ-ULUSZKPHSA-N C[C@H]1N(C)CC(COC(F)F)C1 Chemical compound C[C@H]1N(C)CC(COC(F)F)C1 GXGGNIQWBNKQPJ-ULUSZKPHSA-N 0.000 description 3
- JFYIAHYCTIUEEU-GVHYBUMESA-N C[C@H]1N(C)CC(COC)C1 Chemical compound C[C@H]1N(C)CC(COC)C1 JFYIAHYCTIUEEU-GVHYBUMESA-N 0.000 description 3
- WGNSIHQTQHENSN-RXMQYKEDSA-N C[C@H](C1)N(C)CC1=O Chemical compound C[C@H](C1)N(C)CC1=O WGNSIHQTQHENSN-RXMQYKEDSA-N 0.000 description 2
- OAVDTRCBGZNDIN-ULUSZKPHSA-N C[C@H]1N(C)C(C)CC1 Chemical compound C[C@H]1N(C)C(C)CC1 OAVDTRCBGZNDIN-ULUSZKPHSA-N 0.000 description 2
- VLBZKTFZXUKRRU-ZCFIWIBFSA-N C[C@H]1N(C)N(C)CC1 Chemical compound C[C@H]1N(C)N(C)CC1 VLBZKTFZXUKRRU-ZCFIWIBFSA-N 0.000 description 2
- MYNVQSNSNOJYGF-LLVKDONJSA-N C[C@](C(O)=O)(c1ccccc1)NC(OC)=O Chemical compound C[C@](C(O)=O)(c1ccccc1)NC(OC)=O MYNVQSNSNOJYGF-LLVKDONJSA-N 0.000 description 2
- UOHCHBJFFWIFKI-XJPQQVLCSA-N CC(C(C)OC)C(N1[C@H](C)CC(C)C1)=O Chemical compound CC(C(C)OC)C(N1[C@H](C)CC(C)C1)=O UOHCHBJFFWIFKI-XJPQQVLCSA-N 0.000 description 1
- ZDIMHBHFCKWHOJ-QBWABLMJSA-N CC(C(C)OC)C(N1[C@H](C)CC(COC)C1)=O Chemical compound CC(C(C)OC)C(N1[C@H](C)CC(COC)C1)=O ZDIMHBHFCKWHOJ-QBWABLMJSA-N 0.000 description 1
- KZVMIFXJZQUPKL-UHFFFAOYSA-N CC(C(NC)=O)OC Chemical compound CC(C(NC)=O)OC KZVMIFXJZQUPKL-UHFFFAOYSA-N 0.000 description 1
- AOEHOOSDZSRIQI-UHFFFAOYSA-N CC(C)(C(N(C)N)=O)O Chemical compound CC(C)(C(N(C)N)=O)O AOEHOOSDZSRIQI-UHFFFAOYSA-N 0.000 description 1
- OHPUCEUCBHBIAW-IUCAKERBSA-N CC(C)(C)OC(N(C[C@@H](COC)C1)[C@@H]1C(O)=O)=O Chemical compound CC(C)(C)OC(N(C[C@@H](COC)C1)[C@@H]1C(O)=O)=O OHPUCEUCBHBIAW-IUCAKERBSA-N 0.000 description 1
- SWBZVFFQFKRUQQ-UHFFFAOYSA-N CC(C)(C)OC(NCC(N)=N)=O Chemical compound CC(C)(C)OC(NCC(N)=N)=O SWBZVFFQFKRUQQ-UHFFFAOYSA-N 0.000 description 1
- ANGPNLZHXRGPMC-VOMCLLRMSA-N CC(C)C(C)C(N1[C@H](C)CC(COC)C1)=O Chemical compound CC(C)C(C)C(N1[C@H](C)CC(COC)C1)=O ANGPNLZHXRGPMC-VOMCLLRMSA-N 0.000 description 1
- HPDNHXHMUBENMG-UHFFFAOYSA-N CC(C)CN(CC(O)=O)C(OC(C)(C)C)=O Chemical compound CC(C)CN(CC(O)=O)C(OC(C)(C)C)=O HPDNHXHMUBENMG-UHFFFAOYSA-N 0.000 description 1
- NIXDAMYZONIIOZ-UHFFFAOYSA-N CC(C)CN(CC=O)C(OC(C)(C)C)=O Chemical compound CC(C)CN(CC=O)C(OC(C)(C)C)=O NIXDAMYZONIIOZ-UHFFFAOYSA-N 0.000 description 1
- PDIHCILSOYJLGV-UHFFFAOYSA-N CC(C)CN(Cc([nH]1)ncc1I)C(OC(C)(C)C)=O Chemical compound CC(C)CN(Cc([nH]1)ncc1I)C(OC(C)(C)C)=O PDIHCILSOYJLGV-UHFFFAOYSA-N 0.000 description 1
- VCQNFCLPCFNLEH-UHFFFAOYSA-N CC(C)NC(CC1OCCC1)=O Chemical compound CC(C)NC(CC1OCCC1)=O VCQNFCLPCFNLEH-UHFFFAOYSA-N 0.000 description 1
- KYXJZFVLUAJUPY-UWVGGRQHSA-N CC(C)[C@@H](C(N(CC1(C2)OCCO1)[C@@H]2C(O)=O)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CC1(C2)OCCO1)[C@@H]2C(O)=O)=O)NC(OC)=O KYXJZFVLUAJUPY-UWVGGRQHSA-N 0.000 description 1
- GANIPXNPYMENQJ-WMZOPIPTSA-N CC(C)[C@@H](C(N(CC1(C2)OCCO1)[C@@H]2C(OCC(c(cc1)ccc1Br)=O)=O)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CC1(C2)OCCO1)[C@@H]2C(OCC(c(cc1)ccc1Br)=O)=O)=O)NC(OC)=O GANIPXNPYMENQJ-WMZOPIPTSA-N 0.000 description 1
- WKEUILBJWYDTGX-FZYMCETBSA-N CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@](C)(C3)NCC33OCCO3)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@](C)(C3)NCC33OCCO3)[nH]2)[nH]1)=O)NC(OC)=O WKEUILBJWYDTGX-FZYMCETBSA-N 0.000 description 1
- ATRSLEKRBBYDBG-BBMPLOMVSA-N CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(cc2)cc3c2cc(B2OC(C)(C)C(C)(C)O2)cc3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)C1c1ncc(-c(cc2)cc3c2cc(B2OC(C)(C)C(C)(C)O2)cc3)[nH]1)=O)NC(OC)=O ATRSLEKRBBYDBG-BBMPLOMVSA-N 0.000 description 1
- WBCHFGLRLLBIBW-QSJDGAHRSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c2ccc(cc(cc3)-c(cc4)ccc4-c4cnc([C@H](CC(C5)=O)N5C([C@@H](c5ccccc5)N(C)C)=O)[nH]4)c3c2)c[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1nc(-c2ccc(cc(cc3)-c(cc4)ccc4-c4cnc([C@H](CC(C5)=O)N5C([C@@H](c5ccccc5)N(C)C)=O)[nH]4)c3c2)c[nH]1)=O)NC(OC)=O WBCHFGLRLLBIBW-QSJDGAHRSA-N 0.000 description 1
- VUYHOXAKEKQPAE-SXXQQZPASA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@H](CC(C3)=O)N3C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@H](CC(C3)=O)N3C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O VUYHOXAKEKQPAE-SXXQQZPASA-N 0.000 description 1
- XRZYOWJZCFLHJK-LGFIAEQOSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@H](CCC3)N3C([C@@](C)(c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@H](CCC3)N3C([C@@](C)(c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O XRZYOWJZCFLHJK-LGFIAEQOSA-N 0.000 description 1
- VOZZXMXLPWQCIJ-JXFVTQEHSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@H](C[C@@H](C3)C#N)N3C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc(cc3)c2cc3-c(cc2)ccc2-c2cnc([C@H](C[C@@H](C3)C#N)N3C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O VOZZXMXLPWQCIJ-JXFVTQEHSA-N 0.000 description 1
- OIZHPHLGWNRNBM-YKKXUYLKSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc3c2c(ccc(-c2cnc([C@H](CCC4)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)c2)c2c2nc4ccccc4nc32)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2)cc3c2c(ccc(-c2cnc([C@H](CCC4)N4C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)c2)c2c2nc4ccccc4nc32)[nH]1)=O)NC(OC)=O OIZHPHLGWNRNBM-YKKXUYLKSA-N 0.000 description 1
- CZJLHTLISCSKPK-ACZARZSMSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2OC3)cc(COc4c5)c2-c4c3cc5-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c(cc2OC3)cc(COc4c5)c2-c4c3cc5-c2cnc([C@H](CCC3)N3C([C@H](C(C)C)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O CZJLHTLISCSKPK-ACZARZSMSA-N 0.000 description 1
- QSRMEZUDTBJSTG-UQBQYLODSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c2ccc(cc(cc3)-c(cc4)ccc4-c4cnc([C@H](C[C@H](C)C5)N5C([C@@H](c5ccccc5)NC(OC)=O)=O)[nH]4)c3c2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(-c2ccc(cc(cc3)-c(cc4)ccc4-c4cnc([C@H](C[C@H](C)C5)N5C([C@@H](c5ccccc5)NC(OC)=O)=O)[nH]4)c3c2)[nH]1)=O)NC(OC)=O QSRMEZUDTBJSTG-UQBQYLODSA-N 0.000 description 1
- RFNBOTUQAUSKJR-QSJDGAHRSA-N CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(C(CC2)=CC(CC3)=C2C=C3c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N(CCC1)[C@@H]1c1ncc(C(CC2)=CC(CC3)=C2C=C3c(cc2)ccc2-c2cnc([C@H](CC3(C4)OCCO3)N4C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)[nH]1)=O)NC(OC)=O RFNBOTUQAUSKJR-QSJDGAHRSA-N 0.000 description 1
- MITKJAFAUVYFHV-NHCYSSNCSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c([nH]1)ncc1I)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c([nH]1)ncc1I)=O)NC(OC)=O MITKJAFAUVYFHV-NHCYSSNCSA-N 0.000 description 1
- JYOUNSFYDCPTID-JQTZZUBUSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2)cc3c2-c2cc4ccc5nc([C@H](CCC6)N6C([C@@H](c6ccccc6)NC(OC)=O)=O)[nH]c5c4cc2OC3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2)cc3c2-c2cc4ccc5nc([C@H](CCC6)N6C([C@@H](c6ccccc6)NC(OC)=O)=O)[nH]c5c4cc2OC3)[nH]1)=O)NC(OC)=O JYOUNSFYDCPTID-JQTZZUBUSA-N 0.000 description 1
- XPXLKIFWBRFJOP-GYWKWXFUSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2COc3c4)ccc2-c3cc(cc2)c4c3c2nc([C@H](CCC2)N2C(OC(C)(C)C)=O)[nH]3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2COc3c4)ccc2-c3cc(cc2)c4c3c2nc([C@H](CCC2)N2C(OC(C)(C)C)=O)[nH]3)[nH]1)=O)NC(OC)=O XPXLKIFWBRFJOP-GYWKWXFUSA-N 0.000 description 1
- XDEHMKQLKPZERH-BYPYZUCNSA-N CC(C)[C@@H](C(N)=O)N Chemical compound CC(C)[C@@H](C(N)=O)N XDEHMKQLKPZERH-BYPYZUCNSA-N 0.000 description 1
- ZPLNXFYNXCGNFW-GRYCIOLGSA-N CC(C)[C@@H](C(N1[C@H](C(C)=N)C2=CC[C@@H]1C2)=O)N Chemical compound CC(C)[C@@H](C(N1[C@H](C(C)=N)C2=CC[C@@H]1C2)=O)N ZPLNXFYNXCGNFW-GRYCIOLGSA-N 0.000 description 1
- MDGFWLAYZBCICS-UHFFFAOYSA-N CC(C)c([nH]c1c2)nc1cc1c2c(ccc(-c(cc2)cc(c3c4cncc3)c2c2c4nc(C(C)C)[nH]2)c2)c2[s]1 Chemical compound CC(C)c([nH]c1c2)nc1cc1c2c(ccc(-c(cc2)cc(c3c4cncc3)c2c2c4nc(C(C)C)[nH]2)c2)c2[s]1 MDGFWLAYZBCICS-UHFFFAOYSA-N 0.000 description 1
- UZZRHEGWRHWMRP-UHFFFAOYSA-N CC(C)c1nc(-c(ccc2c3ccc(-c4ccc(c5c(c6c7ccnc6)nc(C(C)C)[nH]5)c7c4)c2)c3OC2)c2[nH]1 Chemical compound CC(C)c1nc(-c(ccc2c3ccc(-c4ccc(c5c(c6c7ccnc6)nc(C(C)C)[nH]5)c7c4)c2)c3OC2)c2[nH]1 UZZRHEGWRHWMRP-UHFFFAOYSA-N 0.000 description 1
- WKWIFRJMIXDGLS-UHFFFAOYSA-N CC(C)c1nc(-c2ccc(cc(cc3)-c(cc4)cc(c5c6ncnc5)c4c4c6nc(C(C)C)[nH]4)c3c2OC2)c2[nH]1 Chemical compound CC(C)c1nc(-c2ccc(cc(cc3)-c(cc4)cc(c5c6ncnc5)c4c4c6nc(C(C)C)[nH]4)c3c2OC2)c2[nH]1 WKWIFRJMIXDGLS-UHFFFAOYSA-N 0.000 description 1
- LAIWVWPBXAZIEL-UHFFFAOYSA-N CC(C)c1nc(c(CCc2c3)c(cc4)-c2ccc3-c(cc2)cc(c3c5ncnc3)c2c2c5nc(C(C)C)[nH]2)c4[nH]1 Chemical compound CC(C)c1nc(c(CCc2c3)c(cc4)-c2ccc3-c(cc2)cc(c3c5ncnc3)c2c2c5nc(C(C)C)[nH]2)c4[nH]1 LAIWVWPBXAZIEL-UHFFFAOYSA-N 0.000 description 1
- OBKGQBIYGYQZOQ-UHFFFAOYSA-N CC(C)c1nc(c2c(c3c4ccc(-c5cc6c(ccnc7)c7c7nc(C)[nH]c7c6cc5)c3)[s]cc2)c4[nH]1 Chemical compound CC(C)c1nc(c2c(c3c4ccc(-c5cc6c(ccnc7)c7c7nc(C)[nH]c7c6cc5)c3)[s]cc2)c4[nH]1 OBKGQBIYGYQZOQ-UHFFFAOYSA-N 0.000 description 1
- SXJWOTPNKFPSBE-UHFFFAOYSA-N CC(C)c1nc(c2c(c3c4ccc(-c5cc6c(cncn7)c7c7nc(C)[nH]c7c6cc5)c3)[s]cc2)c4[nH]1 Chemical compound CC(C)c1nc(c2c(c3c4ccc(-c5cc6c(cncn7)c7c7nc(C)[nH]c7c6cc5)c3)[s]cc2)c4[nH]1 SXJWOTPNKFPSBE-UHFFFAOYSA-N 0.000 description 1
- DHSOEPHDNQFSJL-UHFFFAOYSA-N CC(C)c1nc(c2c(c3cc(-c4cc5c6ncccc6c6nc(C)[nH]c6c5cc4)ccc33)nccn2)c3[nH]1 Chemical compound CC(C)c1nc(c2c(c3cc(-c4cc5c6ncccc6c6nc(C)[nH]c6c5cc4)ccc33)nccn2)c3[nH]1 DHSOEPHDNQFSJL-UHFFFAOYSA-N 0.000 description 1
- LRVPFDMCVMIPHN-UHFFFAOYSA-N CC(C)c1nc(c2cnccc2c2cc(-c3cc4c5ncccc5c5nc(C)[nH]c5c4cc3)ccc22)c2[nH]1 Chemical compound CC(C)c1nc(c2cnccc2c2cc(-c3cc4c5ncccc5c5nc(C)[nH]c5c4cc3)ccc22)c2[nH]1 LRVPFDMCVMIPHN-UHFFFAOYSA-N 0.000 description 1
- FVPAGTQZGANONX-ZDPKUUEZSA-N CC(C)c1nc2c(C)c(/N=C\C)c(cc(cc3)-c4ccc(c5c(c6c7cncn6)nc(C(C)C)[nH]5)c7c4)c3c2[nH]1 Chemical compound CC(C)c1nc2c(C)c(/N=C\C)c(cc(cc3)-c4ccc(c5c(c6c7cncn6)nc(C(C)C)[nH]5)c7c4)c3c2[nH]1 FVPAGTQZGANONX-ZDPKUUEZSA-N 0.000 description 1
- QHUJWSIPSXZQBF-UHFFFAOYSA-N CC(C)c1nc2c(CCc3cc(-c(cc4)cc(c5c6cncc5)c4c4c6nc(C(C)C)[nH]4)ccc3-3)c-3ccc2[nH]1 Chemical compound CC(C)c1nc2c(CCc3cc(-c(cc4)cc(c5c6cncc5)c4c4c6nc(C(C)C)[nH]4)ccc3-3)c-3ccc2[nH]1 QHUJWSIPSXZQBF-UHFFFAOYSA-N 0.000 description 1
- URPLKGQKEWMPRS-UHFFFAOYSA-N CC(C)c1nc2c(cnnc3)c3c(cc(cc3)-c4cc5ccc(-c6c(CC7)nc(C)[nH]6)c7c5[s]4)c3c2[nH]1 Chemical compound CC(C)c1nc2c(cnnc3)c3c(cc(cc3)-c4cc5ccc(-c6c(CC7)nc(C)[nH]6)c7c5[s]4)c3c2[nH]1 URPLKGQKEWMPRS-UHFFFAOYSA-N 0.000 description 1
- HTQUWNDDRVXBIA-UHFFFAOYSA-N CC(C)c1nc2c3[s]c(cc(cc4)-c(cc5)cc(c6c7cncc6)c5c5c7nc(C(C)C)[nH]5)c4c3ccc2[nH]1 Chemical compound CC(C)c1nc2c3[s]c(cc(cc4)-c(cc5)cc(c6c7cncc6)c5c5c7nc(C(C)C)[nH]5)c4c3ccc2[nH]1 HTQUWNDDRVXBIA-UHFFFAOYSA-N 0.000 description 1
- IOFCIJGSIGIUFB-UHFFFAOYSA-N CC(C)c1nc2c3ncncc3c(cc(cc3)-c(cc4)cc(c5c6ncnc5)c4c4c6nc(C(C)C)[nH]4)c3c2[nH]1 Chemical compound CC(C)c1nc2c3ncncc3c(cc(cc3)-c(cc4)cc(c5c6ncnc5)c4c4c6nc(C(C)C)[nH]4)c3c2[nH]1 IOFCIJGSIGIUFB-UHFFFAOYSA-N 0.000 description 1
- ZIWLWADPPJCCQD-UHFFFAOYSA-N CC(C)c1ncc(-c(cc2)cc3c2c(ccc(-c2cnc(C)[nH]2)c2)c2c2nccnc32)[nH]1 Chemical compound CC(C)c1ncc(-c(cc2)cc3c2c(ccc(-c2cnc(C)[nH]2)c2)c2c2nccnc32)[nH]1 ZIWLWADPPJCCQD-UHFFFAOYSA-N 0.000 description 1
- VSMCJLAHVYJKLB-UHFFFAOYSA-N CC(C)c1ncc(-c(cc2CC3)cc(CCc4c5)c2-c4c3cc5-c2cnc(C(C)C)[nH]2)[nH]1 Chemical compound CC(C)c1ncc(-c(cc2CC3)cc(CCc4c5)c2-c4c3cc5-c2cnc(C(C)C)[nH]2)[nH]1 VSMCJLAHVYJKLB-UHFFFAOYSA-N 0.000 description 1
- KIHYGKFUAYPRKZ-UHFFFAOYSA-N CC(C)c1ncc(-c2cc3c(cccc4)c4c(cc(cc4)-c5cnc(C)[nH]5)c4c3cc2)[nH]1 Chemical compound CC(C)c1ncc(-c2cc3c(cccc4)c4c(cc(cc4)-c5cnc(C)[nH]5)c4c3cc2)[nH]1 KIHYGKFUAYPRKZ-UHFFFAOYSA-N 0.000 description 1
- DRFFRGFXEIMLRX-PRJDIBJQSA-N CC(C1)CN(C)[C@@H]1S Chemical compound CC(C1)CN(C)[C@@H]1S DRFFRGFXEIMLRX-PRJDIBJQSA-N 0.000 description 1
- YATZEKYNRHCFMA-UHFFFAOYSA-N CC(C1NCNC)N1NC Chemical compound CC(C1NCNC)N1NC YATZEKYNRHCFMA-UHFFFAOYSA-N 0.000 description 1
- ZTFVDYHMOINIES-QVBJCFTNSA-N CCC(C)C(C)C(N1[C@H](C)CC(COC)C1)=O Chemical compound CCC(C)C(C)C(N1[C@H](C)CC(COC)C1)=O ZTFVDYHMOINIES-QVBJCFTNSA-N 0.000 description 1
- QJQAMHYHNCADNR-UHFFFAOYSA-N CCC(NC)=O Chemical compound CCC(NC)=O QJQAMHYHNCADNR-UHFFFAOYSA-N 0.000 description 1
- ZUCSUKWYYWJTHM-UHFFFAOYSA-N CCN(CC)C(C(O)=O)c1ccccc1 Chemical compound CCN(CC)C(C(O)=O)c1ccccc1 ZUCSUKWYYWJTHM-UHFFFAOYSA-N 0.000 description 1
- DRVMAWVATQDXEF-UHFFFAOYSA-N CCc([nH]c1c2)nc1cc1c2c(ccc(-c2ccc(c3c(c4c5cncn4)nc(C(C)C)[nH]3)c5c2)c2)c2[s]1 Chemical compound CCc([nH]c1c2)nc1cc1c2c(ccc(-c2ccc(c3c(c4c5cncn4)nc(C(C)C)[nH]3)c5c2)c2)c2[s]1 DRVMAWVATQDXEF-UHFFFAOYSA-N 0.000 description 1
- KGDMFCKWIARDOQ-UHFFFAOYSA-N CCc1nc(COc2c-3ccc4c2[s]c(-c(cc2)cc(c5c6cncc5)c2c2c6nc(C(C)C)[nH]2)c4)c-3[nH]1 Chemical compound CCc1nc(COc2c-3ccc4c2[s]c(-c(cc2)cc(c5c6cncc5)c2c2c6nc(C(C)C)[nH]2)c4)c-3[nH]1 KGDMFCKWIARDOQ-UHFFFAOYSA-N 0.000 description 1
- VUHCOJSTFLMUPI-UHFFFAOYSA-N CN(C(CC1CCOCC1)=O)N Chemical compound CN(C(CC1CCOCC1)=O)N VUHCOJSTFLMUPI-UHFFFAOYSA-N 0.000 description 1
- RYSKBXGRUZUSED-MLWJPKLSSA-N CN(CC(COC)C1)[C@@H]1N Chemical compound CN(CC(COC)C1)[C@@H]1N RYSKBXGRUZUSED-MLWJPKLSSA-N 0.000 description 1
- BVNIREPGHLFKNZ-UHFFFAOYSA-N CNC(C1CC1)=O Chemical compound CNC(C1CC1)=O BVNIREPGHLFKNZ-UHFFFAOYSA-N 0.000 description 1
- GXBQFPDPMJZGCH-UHFFFAOYSA-N CNC(CC1COC1)=O Chemical compound CNC(CC1COC1)=O GXBQFPDPMJZGCH-UHFFFAOYSA-N 0.000 description 1
- KGVBQXLYAHIEBB-UHFFFAOYSA-N CNC(N1CCOCC1)=O Chemical compound CNC(N1CCOCC1)=O KGVBQXLYAHIEBB-UHFFFAOYSA-N 0.000 description 1
- NYXHSRNBKJIQQG-UHFFFAOYSA-N CNC(OC)=O Chemical compound CNC(OC)=O NYXHSRNBKJIQQG-UHFFFAOYSA-N 0.000 description 1
- JNGJIVXXIVLRHR-UHFFFAOYSA-N CNC(OC1COC1)=O Chemical compound CNC(OC1COC1)=O JNGJIVXXIVLRHR-UHFFFAOYSA-N 0.000 description 1
- XGFYAAUZMZFRRN-UHFFFAOYSA-N CNc1cncnc1 Chemical compound CNc1cncnc1 XGFYAAUZMZFRRN-UHFFFAOYSA-N 0.000 description 1
- FPFAVWMBTWVWMG-WRQZLFHVSA-N CO/C(/N)=[O]/c1c(CC(N(CCC2)[C@@H]2c2nc3ccc(cc(cc4)-c(ccc5c6)cc5ccc6-c5cnc([C@H](CCC6)N6C([C@H](C6CCOCC6)NC(OC)=O)=O)[nH]5)c4c3[nH]2)=O)cccc1 Chemical compound CO/C(/N)=[O]/c1c(CC(N(CCC2)[C@@H]2c2nc3ccc(cc(cc4)-c(ccc5c6)cc5ccc6-c5cnc([C@H](CCC6)N6C([C@H](C6CCOCC6)NC(OC)=O)=O)[nH]5)c4c3[nH]2)=O)cccc1 FPFAVWMBTWVWMG-WRQZLFHVSA-N 0.000 description 1
- CSNCHEVKUIPVLM-SECBINFHSA-N COC(N[C@@H](C(O)=O)c1cc(OC)ccc1)=O Chemical compound COC(N[C@@H](C(O)=O)c1cc(OC)ccc1)=O CSNCHEVKUIPVLM-SECBINFHSA-N 0.000 description 1
- GOJLQSAREKTKPT-MRVPVSSYSA-N COC(N[C@@H](C(O)=O)c1ccccc1)=O Chemical compound COC(N[C@@H](C(O)=O)c1ccccc1)=O GOJLQSAREKTKPT-MRVPVSSYSA-N 0.000 description 1
- UMKVNPOZWRHJPM-UHFFFAOYSA-N COc1cccc(C(C(O)=O)N)c1 Chemical compound COc1cccc(C(C(O)=O)N)c1 UMKVNPOZWRHJPM-UHFFFAOYSA-N 0.000 description 1
- DUKUKJFQHYTCIA-JQWIXIFHSA-N C[C@@H](C[C@H]1C(O)=O)CN1C(OCc1ccccc1)=O Chemical compound C[C@@H](C[C@H]1C(O)=O)CN1C(OCc1ccccc1)=O DUKUKJFQHYTCIA-JQWIXIFHSA-N 0.000 description 1
- OTXLPVNSCQAIAI-ULUSZKPHSA-N C[C@H](CC(COC)C1)N1N Chemical compound C[C@H](CC(COC)C1)N1N OTXLPVNSCQAIAI-ULUSZKPHSA-N 0.000 description 1
- FILVIKOEJGORQS-RXMQYKEDSA-N C[C@H](CC1)N(C)C1=O Chemical compound C[C@H](CC1)N(C)C1=O FILVIKOEJGORQS-RXMQYKEDSA-N 0.000 description 1
- OLKABNQIGLMXQC-RXMQYKEDSA-N C[C@H](CCC1=O)N1NC Chemical compound C[C@H](CCC1=O)N1NC OLKABNQIGLMXQC-RXMQYKEDSA-N 0.000 description 1
- JAOYAXFZIAGXFI-LWOQYNTDSA-N C[C@H](CCC1C)N1N Chemical compound C[C@H](CCC1C)N1N JAOYAXFZIAGXFI-LWOQYNTDSA-N 0.000 description 1
- HSKFWUNQSAWFDR-SCSAIBSYSA-N C[C@H](CO1)N(C)C1=O Chemical compound C[C@H](CO1)N(C)C1=O HSKFWUNQSAWFDR-SCSAIBSYSA-N 0.000 description 1
- PAISMPKJXOZRKI-UHNVWZDZSA-N C[C@H]([C@@H](C(O)=O)NC(OC)=O)OC Chemical compound C[C@H]([C@@H](C(O)=O)NC(OC)=O)OC PAISMPKJXOZRKI-UHNVWZDZSA-N 0.000 description 1
- MUKOYRJZZPTNHT-ZCFIWIBFSA-N C[C@H]1N(C)C=CC1 Chemical compound C[C@H]1N(C)C=CC1 MUKOYRJZZPTNHT-ZCFIWIBFSA-N 0.000 description 1
- HTCSFFGLRQDZDE-SECBINFHSA-N C[C@](C(O)=O)(c1ccccc1)N Chemical compound C[C@](C(O)=O)(c1ccccc1)N HTCSFFGLRQDZDE-SECBINFHSA-N 0.000 description 1
- FOJGKGUHIMZFDZ-SSVKRKGOSA-N Cc1c2nc([C@H](CCC3)N3C([C@H](C3CCOCC3)NC(OC)=O)=O)[nH]c2c(ccc(-c(ccc2c3)cc2ccc3-c2cnc([C@H]([C@@H]3C[C@H]4CC3)N4C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)c2)c2c1 Chemical compound Cc1c2nc([C@H](CCC3)N3C([C@H](C3CCOCC3)NC(OC)=O)=O)[nH]c2c(ccc(-c(ccc2c3)cc2ccc3-c2cnc([C@H]([C@@H]3C[C@H]4CC3)N4C([C@@H](c3ccccc3)NC(OC)=O)=O)[nH]2)c2)c2c1 FOJGKGUHIMZFDZ-SSVKRKGOSA-N 0.000 description 1
- UCOFHRBXPXFFNU-UHFFFAOYSA-N Cc1nc(CCc2c3[s]c(-c4cc5c(cccc6)c6c6nc(C)[nH]c6c5cc4)cc3ccc2-2)c-2[nH]1 Chemical compound Cc1nc(CCc2c3[s]c(-c4cc5c(cccc6)c6c6nc(C)[nH]c6c5cc4)cc3ccc2-2)c-2[nH]1 UCOFHRBXPXFFNU-UHFFFAOYSA-N 0.000 description 1
- JDBNUJXKPMFCND-UHFFFAOYSA-N Cc1ncc(-c(cc2CC3)cc(CCc4c5)c2-c4c3cc5-c(cc2)cc3c2nc(C)[nH]3)[nH]1 Chemical compound Cc1ncc(-c(cc2CC3)cc(CCc4c5)c2-c4c3cc5-c(cc2)cc3c2nc(C)[nH]3)[nH]1 JDBNUJXKPMFCND-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N O=C(CBr)c(cc1)ccc1Br Chemical compound O=C(CBr)c(cc1)ccc1Br FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- MLAIANMWUQDKFB-UHFFFAOYSA-N O=C(CBr)c(cc1OCc2cc(C(CBr)=O)c3)cc4c1-c2c3OC4 Chemical compound O=C(CBr)c(cc1OCc2cc(C(CBr)=O)c3)cc4c1-c2c3OC4 MLAIANMWUQDKFB-UHFFFAOYSA-N 0.000 description 1
- MNZONBWXVOXEBH-NSHDSACASA-N O=C([C@H](C1)NCC1=O)OCc1ccccc1 Chemical compound O=C([C@H](C1)NCC1=O)OCc1ccccc1 MNZONBWXVOXEBH-NSHDSACASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41481810P | 2010-11-17 | 2010-11-17 | |
US61/414,818 | 2010-11-17 | ||
US201161504924P | 2011-07-06 | 2011-07-06 | |
US61/504,924 | 2011-07-06 | ||
PCT/US2011/060966 WO2012068234A2 (en) | 2010-11-17 | 2011-11-16 | Antiviral compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197002491A Division KR20190012271A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020207034568A Division KR20200140924A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190140486A true KR20190140486A (ko) | 2019-12-19 |
Family
ID=45099196
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020197036217A KR20190140486A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
KR1020207034568A KR20200140924A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
KR1020197002491A KR20190012271A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
KR1020187005807A KR20180026563A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
KR1020137015201A KR101835474B1 (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020207034568A KR20200140924A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
KR1020197002491A KR20190012271A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
KR1020187005807A KR20180026563A (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
KR1020137015201A KR101835474B1 (ko) | 2010-11-17 | 2011-11-16 | 항바이러스 화합물 |
Country Status (18)
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
CN109020961A (zh) | 2009-05-13 | 2018-12-18 | 吉利德制药有限责任公司 | 抗病毒化合物 |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
DK2455376T3 (en) | 2009-06-11 | 2015-03-02 | Abbvie Bahamas Ltd | Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) |
CA2800530A1 (en) * | 2010-05-28 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
JP5905020B2 (ja) | 2010-11-17 | 2016-04-20 | ギリアド ファーマセット エルエルシー | 抗ウイルス化合物 |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN104244945B (zh) | 2011-09-16 | 2016-08-31 | 吉利德制药有限责任公司 | 用于治疗hcv的方法 |
PT3431477T (pt) | 2011-11-16 | 2020-12-15 | Gilead Pharmasset Llc | Imidazolilimidazolos condensados como compostos antivirais |
AU2015252077A1 (en) * | 2011-11-16 | 2015-11-19 | Gilead Pharmasset Llc | Antiviral compounds |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2812326A1 (en) | 2012-02-10 | 2014-12-17 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
US9079887B2 (en) * | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
US9233974B2 (en) * | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
SG11201506021XA (en) | 2013-01-31 | 2015-08-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN105121428B (zh) * | 2013-02-07 | 2019-12-24 | 九州有机光材股份有限公司 | 具有二氮杂苯并菲环结构的化合物和有机电致发光器件 |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
WO2014185995A1 (en) * | 2013-05-16 | 2014-11-20 | Gilead Pharmasset Llc | Hepatitis c treatments with sofosbuvir |
CN104211677B (zh) * | 2013-05-30 | 2018-02-23 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
US9902693B2 (en) | 2013-06-26 | 2018-02-27 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | Preparation method for pyrrolidine-2-carboxylic acid derivatives |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
US20150064252A1 (en) * | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
PT3650014T (pt) * | 2013-08-27 | 2021-12-27 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
WO2015089810A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
CN105873922B (zh) * | 2013-12-31 | 2018-08-14 | 南京圣和药业股份有限公司 | 9,9,10,10-四氟-9,10二氢菲类丙型肝炎病毒抑制剂及其应用 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
TWI679203B (zh) | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
PT3154985T (pt) * | 2014-06-12 | 2018-10-19 | Gilead Sciences Inc | Compostos antivirais |
CA2972259A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN104592124B (zh) * | 2015-01-04 | 2018-01-02 | 华南理工大学 | 一种萘[1,2]并咪唑双极性共轭化合物及制备与应用 |
CN105968101B (zh) * | 2015-03-12 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
WO2016202232A1 (zh) * | 2015-06-19 | 2016-12-22 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
CN106256819B (zh) * | 2015-06-19 | 2019-07-09 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR101919194B1 (ko) * | 2015-09-15 | 2018-11-15 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
WO2017181383A1 (en) | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
CN106432197B (zh) * | 2016-09-07 | 2019-12-10 | 上海众强药业有限公司 | 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法 |
CN107805256B (zh) * | 2016-11-30 | 2020-03-31 | 上海博志研新药物技术有限公司 | 维帕他韦中间体及制备方法和应用 |
WO2018138050A1 (de) | 2017-01-26 | 2018-08-02 | Bayer Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
KR102316919B1 (ko) | 2019-11-28 | 2021-10-22 | 서울시립대학교 산학협력단 | 피지컬 컴퓨팅 소프트웨어를 이용한 코딩 교육 교재 및 이를 활용한 코딩 교육 방법 |
CN111018870B (zh) * | 2019-11-29 | 2021-07-23 | 南京正济医药研究有限公司 | 一种维帕他韦中间体的制备方法 |
EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
EP4341267A1 (en) * | 2021-05-21 | 2024-03-27 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
EP4341266A1 (en) * | 2021-05-21 | 2024-03-27 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
AU651835B2 (en) | 1990-06-13 | 1994-08-04 | Arnold Glazier | Phosphorous prodrugs |
ATE167679T1 (de) | 1990-09-14 | 1998-07-15 | Acad Of Science Czech Republic | Wirkstoffvorläufer von phosphonaten |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
JP4584909B2 (ja) | 2003-05-09 | 2010-11-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎ウイルスns5bポリメラーゼインヒビター結合ポケット |
US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
EP1778702B1 (en) | 2004-07-16 | 2011-07-13 | Gilead Sciences, Inc. | Antiviral compounds |
US7875278B2 (en) * | 2005-02-18 | 2011-01-25 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JPWO2008069262A1 (ja) | 2006-12-07 | 2010-03-25 | 第一三共株式会社 | 安定性が改善されたフィルムコーティング製剤 |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PT2250163E (pt) | 2008-02-12 | 2012-06-01 | Bristol Myers Squibb Co | Inibidores do vírus da hepatite c |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2010008863A (es) * | 2008-02-13 | 2010-09-07 | Bristol Myers Squibb Co | Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c. |
US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
US8729077B2 (en) * | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
KR20110098779A (ko) | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Hcv ns5a의 억제제 |
CA2753313A1 (en) * | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
EP2400846B1 (en) | 2009-02-27 | 2016-10-05 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
BRPI1012282A2 (pt) | 2009-03-27 | 2015-09-22 | Presidio Pharmaceuticals Inc | inibidores de anel fundidos da hepatite c. |
WO2010111673A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
EP2430015B1 (en) | 2009-05-12 | 2015-06-17 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds useful for the treatment of viral diseases |
CN109020961A (zh) * | 2009-05-13 | 2018-12-18 | 吉利德制药有限责任公司 | 抗病毒化合物 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EA201290089A1 (ru) * | 2009-09-04 | 2012-09-28 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Химические соединения |
WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
CA2782024A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102791687B (zh) | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
AU2010341537A1 (en) | 2009-12-22 | 2012-08-09 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases |
SG183526A1 (en) * | 2010-03-09 | 2012-09-27 | Merck Sharp & Dohme | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
US9125904B1 (en) * | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
US20110312996A1 (en) | 2010-05-17 | 2011-12-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
CA2809261A1 (en) | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
JP5905020B2 (ja) | 2010-11-17 | 2016-04-20 | ギリアド ファーマセット エルエルシー | 抗ウイルス化合物 |
WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
PT3431477T (pt) | 2011-11-16 | 2020-12-15 | Gilead Pharmasset Llc | Imidazolilimidazolos condensados como compostos antivirais |
US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
PT3650014T (pt) | 2013-08-27 | 2021-12-27 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
US20150064252A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
TWI679203B (zh) | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
-
2011
- 2011-11-16 JP JP2013539970A patent/JP5905020B2/ja active Active
- 2011-11-16 EP EP19215845.9A patent/EP3699176A3/en not_active Withdrawn
- 2011-11-16 KR KR1020197036217A patent/KR20190140486A/ko active Application Filing
- 2011-11-16 SG SG2013036223A patent/SG190785A1/en unknown
- 2011-11-16 PL PL11791700T patent/PL2640719T3/pl unknown
- 2011-11-16 NZ NZ710567A patent/NZ710567A/en unknown
- 2011-11-16 ES ES11791700.5T patent/ES2634095T3/es active Active
- 2011-11-16 SI SI201131200A patent/SI2640719T1/sl unknown
- 2011-11-16 UY UY33735A patent/UY33735A/es not_active Application Discontinuation
- 2011-11-16 EP EP11791700.5A patent/EP2640719B1/en active Active
- 2011-11-16 EP EP17169675.0A patent/EP3284741A1/en not_active Withdrawn
- 2011-11-16 WO PCT/US2011/060966 patent/WO2012068234A2/en active Application Filing
- 2011-11-16 US US13/884,578 patent/US9156823B2/en active Active
- 2011-11-16 KR KR1020207034568A patent/KR20200140924A/ko not_active Application Discontinuation
- 2011-11-16 PT PT117917005T patent/PT2640719T/pt unknown
- 2011-11-16 KR KR1020197002491A patent/KR20190012271A/ko not_active Application Discontinuation
- 2011-11-16 TW TW106129863A patent/TWI640526B/zh active
- 2011-11-16 TW TW105118984A patent/TWI607011B/zh active
- 2011-11-16 KR KR1020187005807A patent/KR20180026563A/ko not_active Application Discontinuation
- 2011-11-16 CA CA2817840A patent/CA2817840A1/en not_active Abandoned
- 2011-11-16 CA CA3102625A patent/CA3102625C/en active Active
- 2011-11-16 NZ NZ726475A patent/NZ726475A/en unknown
- 2011-11-16 TW TW100141839A patent/TWI548629B/zh active
- 2011-11-16 AU AU2011328980A patent/AU2011328980B2/en active Active
- 2011-11-16 CA CA3095528A patent/CA3095528C/en active Active
- 2011-11-16 AR ARP110104276 patent/AR083711A1/es active IP Right Grant
- 2011-11-16 SG SG10201509456SA patent/SG10201509456SA/en unknown
- 2011-11-16 KR KR1020137015201A patent/KR101835474B1/ko active IP Right Grant
-
2013
- 2013-05-13 IL IL226346A patent/IL226346A/en active IP Right Grant
-
2015
- 2015-07-30 US US14/814,392 patent/US10344019B2/en active Active
-
2016
- 2016-03-15 JP JP2016051146A patent/JP2016106149A/ja active Pending
-
2017
- 2017-04-13 AU AU2017202461A patent/AU2017202461A1/en not_active Abandoned
- 2017-12-15 JP JP2017240524A patent/JP2018039851A/ja not_active Withdrawn
-
2018
- 2018-07-24 HK HK18109580.7A patent/HK1250162A1/zh unknown
-
2019
- 2019-03-20 AU AU2019201939A patent/AU2019201939C1/en active Active
- 2019-05-23 US US16/421,330 patent/US20200123132A1/en not_active Abandoned
- 2019-11-15 JP JP2019206819A patent/JP2020037584A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019201939B2 (en) | Antiviral compounds | |
KR101890400B1 (ko) | 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸 | |
AU2019202345B2 (en) | Antiviral Compounds | |
AU2015243078A1 (en) | Antiviral compounds | |
OA17167A (en) | Condensed imidazolylimidazoles as antiviral compounds. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
A107 | Divisional application of patent |